Series A financing highlights the potential impact of Abselion’s technology for life science research and bioprocess development
[Cambridge, UK, December 4, 2024] – Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.
This cutting-edge benchtop instrument allows scientists to easily quantify antibodies, AAVs, and other proteins directly from crude samples in as little as one minute, providing critical data on the spot, enhancing efficiency and accuracy in life science research and bioprocessing.
The funding round, led by M Ventures (the strategic, corporate venture capital arm of science and technology company Merck), includes new investors BioProcess 360 Partners and Untitled Ventures, along with BGF, R42 and other existing investors. Oliver Hardick of M Ventures and Chris Major of BioProcess 360 Partners have joined the Company’s new Board of Directors.
Abselion will use the funds to drive the commercialisation and expand the capabilities of its Amperia system. Built on proprietary Redox Electrochemical Detection (RED) technology, Amperia brings a groundbreaking approach to biologics and viral-vector quantification for confident, convenient and cost-effective automated at-line measurement that is accessible to all laboratories and process environments.
“We are delighted to have the support of our investment partners to advance our mission to provide scientists with critical real-time data at the point of need,” says Ruizhi Wang, CEO of Abselion. “The Amperia RED technology delivers the accuracy, speed and agility required for insights that enable confident decision-making, driving bioprocess optimisation and innovation.” Dr. Oliver Hardick, of M Ventures, commented: “Providing meaningful data as close to the process as possible is a crucial pillar of enabling improved bioprocess development and manufacturing robustness. Abselion’s Amperia system does exactly this by delivering gold-standard insights in minutes that Bioprocess teams typically wait days for. We are thrilled to lead this financing alongside our co-investors and to partner with the Abselion team as they expand this technology and broaden its technical capability through 2025 and beyond. We believe this will disrupt how Process Development operates today, and we invite our colleagues in the industry to reach out to me or the Abselion team to explore this further.”
For media enquiries, please contact:
Helen Manley
Abselion
info@abselion.com
About Abselion
Abselion is a Cambridge, UK-based innovator in automated analytical instrumentation simplifying at-line protein analytics for the development and production of biologics, such as antibodies and viral vectors. Pioneering the highly sensitive and specific, Redox-Electrochemical-Detection (RED) technology, Abselion seeks to streamline and accelerate access to process insights in biopharmaceutical research, development and production. Abselion combines the expertise of an interdisciplinary team working at the intersection of biology, nanotechnology and engineering. Learn more at www.abselion.com or follow us on LinkedIn @abselion.
About M Ventures
M Ventures is the strategic, corporate venture capital fund of Merck. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs in the areas of healthcare drug development, life science tools, electronics and frontier technology & sustainability. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck’s current and future businesses. For more information, visit www.m-ventures.com.
About BioProcess360 Partners
BioProcess 360 Partners provides inflection, growth capital and hands-on expertise for the most innovative emerging technologies in Bioprocessing. For more information, visit www.bioprocess360.com
About BGF
BGF was set up in 2011 and has invested £4 billion in over 600 companies to date making it the most active investor in the UK. BGF is a minority, non-controlling equity partner with a patient outlook on investments, based on shared long-term goals with the management teams it backs. Learn more at: www.bgf.co.uk
About Untitled Ventures
Untitled is an investment firm offering a range of private capital solutions to fund transformative technologies. Our strategies encompass industrial transformation, life sciences and fund-of-funds. Untitled Life Science is an early-stage fund with focuses on disruptive innovation in therapeutics, life sciences tools and synthetic biology. Learn more at: www.untitled.co
About R42
R42 actively invents and finances deep science ventures. We help entrepreneurs turn their own ideas and visions into successful companies. Learn more at: www.r42group.com